Loading
No insider purchase over the last 90 days. The latest, by Paweł Holstinghausen Holsten, was filed 27 Nov 2025.
Captor Therapeutics S.A. is a listed company. Filings by its managers are published through KNF. 6 insiders have disclosed 8 filings since 24 October 2025.
No insider sold shares on the market over the period. Instead, the filings list 3 purchases totalling €48k, made by 3 insiders. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The largest single trade was a purchase of €22k by Paweł Holstinghausen Holsten, published on 27 November 2025.
The data flag 2 purchases as part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The last purchase on record was published on 27 November 2025, which is 330 days ago. Between a trade and the moment it shows up on KNF, the median delay is 1 day. Under the Market Abuse Regulation, managers have three business days to notify their trades.
Compared with its exchange (554 companies, median 3 filings), a count of 8 filings is above the norm. Looking back to 2025, when coverage begins, insiders filed 3 purchases and no sales.
This summary is built from KNF disclosures alone and does not predict where the share price will go.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
· cache
8 of 8 declarations
Captor Therapeutics S.A. is a company focused on developing innovative therapies for disease treatment. It is listed on the XWAR market.